Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells

Journal of Cellular Physiology

Volumn 201, Issue 1, 2004, Pages 97-105

  Sgambato, Alessandro ^a,b   Camerini, Andrea ^a   Faraglia, Beatrice ^a   Ardito, Raffaele ^a   Bianchino, Gabriella ^a,b   Spada, Daniele ^a   Boninsegna, Alma ^a   Valentini, Vincenzo ^c   Cittadini, Achille ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; CYCLIN D1; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FLUTAMIDE; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL ASSAY; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; ENZYME INHIBITION; FLOW CYTOMETRY; GROWTH INHIBITION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; IONIZING RADIATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; FLUTAMIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 4444242518     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20045     Document Type: Article

References (46)

1. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. 2001. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911-1914.
2. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F. 2002. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250-3258.
3. Brogden RN, Clissold SP. 1989. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 38:185-203.
4. Carrano AC, Eytan E, Hershko A, Pagano M. 1999. SKP2 is required for ubiquitin-mdiated degradation of the CDK inhibitor p27Kip1. Nat Cell Biol 1:193-199.
5. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. 1993. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23: 123-134.
6. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JC. 1993. Expression of mRNA for epidermal growth factor, transforming growth fcator-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126:151-158.
7. Ciardiello F, Tortora F. 2001. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970.
8. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
9. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. 2003a. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987.
10. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. 2003b. FDA drug approval summary: Gefitinib (ZD1839) (Iressa®) tablets. The Oncologist 8:303-306.
11. Connolly JM, Rose DPTP. 1989. Secretion of epidermal growth factor and related polypeptides by the DU145 human prostate cancer cell line. Prostate 15:177-186.
12. Connolly JM, Rose DP. 1990. Production of epidermal growth factor and transforming growth factor-a by the androgen-responsive LNCap human prostate cancer cell line. Prostate 16:209-218.
13. Connolly JM, Rose DP. 1991. Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19:173-180.
14. Davies P, Eaton CL. 1989. Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate. Prostate 14:123-132.
15. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Canaglia M, Abruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A. 2003. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195:139-150.
16. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. 2003. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:www.jco.org.
17. Glynne-Jones E, Goddard L, Harper M. 1996. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 27:688-694.
18. Guo C, Luttrell LM, Price DT. 2000. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163: 1027-1032.
19. Han EK, Sgambato A, Jiang W, Zhang Y, Santella RM, Doki Y, Cacace AM, Schieren I, Weinstein IB. 1995. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 10:953-962.
20. 1 transition mediated by a Skp2-independent ubiquination pathway. J Biol Chem 276:48937-48943.
21. Harper ME, Goddard L, Glynne-Jones E, Peeling WB, Griffiths K. 1995. Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours. Eur J Cancer 31A:1492-1497.
22. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM, Agoaihpccrotgfa CR. 1991. Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor α. Cancer Res 51:2780-2785.
23. Huang S-M, Li J, Armstrong EA, Harari PM. 2002. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306.
24. Isaacs WB, Carter BS, Ewing CM. 1991. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.
25. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. 1994. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24:46-53.
26. Kris M, Natale RB, Herbst R, Lynch T, Prager D, Belani C, Schiller JH, Kelly K, Spiridonidis CH, Albain KS, Brahmer J, Crawford J, Lutzker S, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A. 2002. A phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a.
27. Maddy SQ, Chisholm GD, Hawkins R, Habib FK. 1987. Localization of epidermal growth factor receptor in human prostate by biochemical and immunohistochemical methods. J Endocrinol 183:147-153.
28. Maddy SQ, Chisholm GD, Busuttil A, Habib FK. 1989. Epidermal growth factor receptors in human prostate cancer: Correlation with histological differentiation of the tumour. Br J Cancer 60:41-44.
29. Myers RB, Kudlow JE, Grizzle WE. 1993. Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Pathol 6:733-737.
30. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H. 1999. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59:227-233.
31. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
32. kip1. Cancer Res 56:1389-1399.
33. Kip1 expression. Cell Growth Differ 8:393-405.
34. Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells. Cancer Res 58:3448-3454.
35. Kip1 in human colon cancer. Mol Carcinogenesis 26:172-179.
36. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A. 2001. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mut Res 496:171-180.
37. Sgambato A, Camerini A, Pani G, Cangiano R, Faraglia B, Bianchino G, De Bari B, Galeotti T, Cittadini A. 2003. Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer 88:1956-1962.
38. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. 2002. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 8: 3870-3876.
39. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, Mcarthur GA, Cullinane C. 2003. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 55:713-723.
40. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. 2003. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 129:165-174.
41. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. 2002. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754.
42. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. 2002. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86:1157-1161.
43. Woodburn J. 1999. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250.
44. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-1403.
45. Xie HY, Turner T, Wang M-H, Singh RK, Siegal GP, Wells A. 1995. In vitro invasiveness of DU145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 13:407-419.
46. Ye D, Mendelsohn J, Fan Z. 1999. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa2a and MDA PCa2b prostate cancer cells. Clin Cancer Res 5:2171-2177.